Abstract
Osteosarcoma, one of the most common primary bone malignances, is a leading cause of cancer death among children and adolescents. Recently, growing studies have found that long non-coding RNAs (lncRNAs) can interfere with the expression of various genes, and participate in the occurrence and development of malignancies. The purpose of this study is to evaluate the potential functions of lncRNAs as diagnostic biomarkers and therapeutic targets for osteosarcoma in mice, thus to direct the strict design for the future preclinical experiments and clinical trials. We systematically searched PubMed, Web of Science, Embase, China Knowledge Resource Integrated Database, VIP, Chinese BioMedical and Wan Fang Database from their initiation date to June 20, 2017. Two researchers independently screened the literatures and withdrew the data, which used the tumor volume and tumor weight as the outcome measures. A total of 10 studies were included, and the results of this meta-analysis revealed that lncRNAs could serve as the diagnostic biomarkers and therapeutic targets for osteosarcoma; and progression of osteosarcoma in mice could be inhibited via rescuing the abnormally expressed lncRNAs. It is necessary to carry out more rigorous basic experiments before lncRNAs can be further investigated in the clinical trials and used in future clinical practices.
Highlights
Osteosarcoma is one of the most common primary bone malignancies, which often arises in the distal femur, proximal tibia, and proximal humerus
The purpose of this article is to evaluate the potential functions of long non-coding RNAs (lncRNAs) as diagnostic biomarkers and therapeutic targets for osteosarcoma according to the published literatures; and to investigate the methodological quality of current studies to direct the strict design of the future preclinical experiments and clinical trials
Accumulating reports of lncRNAs on osteosarcoma in the mouse models implied that many lncRNAs could promote the progression of tumor in vivo, while the tumor volume and tumor weight were significantly decreased by down-regulating the expressions of these lncRNAs
Summary
Osteosarcoma is one of the most common primary bone malignancies, which often arises in the distal femur, proximal tibia, and proximal humerus. Its incidence approximately makes up 60% of all children malignant bone tumors, especially among the males. Osteosarcoma is a leading cause of cancer death among children and adolescents [1, 2]. With the progression of neoadjuvant chemotherapy and surgical treatment, the survival rate of osteosarcoma patients has been improved. The 5-year survival rate of patients with localized osteosarcoma is up to 80%, while only 20% of those with metastatic or recurrent disease can survive more than 5 years [3, 4]. It is of great significance to seek out more effective diagnostic biomarkers and therapeutic targets for clinical treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
